Low-dose naltrexone offers a great commitment to the millions of people all over the world dealing with autoimmune diseases, central nervous system disorders, or people facing deadly cancer. Because In such an innovative world, LDN can provide the initial cost-friendly, easy to take, and side-effect-free treatment for HIV/AIDS.
In 1984 FDA approved naltrexone itself in a dose of 50mg for the objective of treating heroin or opium abusers by obstructing the euphoric influence of such drugs. Through inhibiting opioid receptors, naltrexone further blocks the binding of the opioid hormones, which are produced in our brain and adrenal glands such as metenkephalin and beta-endorphin. Various tissues of the body own receptors for these enkephalins and endorphins, so involving practically all the cells of the body’s immune system.
List of the diseases has it been helpful for:
- Bladder Cancer
- Breast Cancer
- Colon & Rectal Cancer
- Liver Cancer
- Lung Cancer (Non-Small Cell)
- Lymphoma (Hodgkin’s and Non-Hodgkin’s)
- Lymphocytic Leukemia (chronic)
- Multiple Myeloma
- Malignant Melanoma
- Pancreatic Cancer
- Ovarian Cancer
- Prostate Cancer
- Throat Cancer
- Renal Cell Carcinoma
- Uterine Cancer
- Common Colds (URI’s)
- Emphysema (COPD)
- Lyme Disease (Late Stage)
- Depression (Major and Bipolar)
- ALS (Lou Gehrig’s Disease)
- Autism Spectrum Disorders
- Alzheimer’s Disease
- Multiple Sclerosis (MS)
- Hereditary Spastic Paraparesis
- Parkinson’s Disease
- Post-Traumatic Stress Disorder (PTSD)
- Post-Polio Syndrome
- Progressive Supranuclear Palsy
- Primary Lateral Sclerosis (PLS)
- Transverse Myelitis
Other Autoimmune Diseases:
- Behcet’s Disease
- Ankylosing Spondylitis
- Crohn’s Disease
- Celiac Disease
- CREST syndrome
- Chronic Fatigue Syndrome
- Hashimoto’s Thyroiditis
- Irritable Bowel Syndrome (IBS)
- Nephrotic Syndrome
- Myasthenia Gravis (MG)
- Primary Biliary Cirrhosis
- Stiff Person Syndrome (SPS)
- Rheumatoid Arthritis
- Sjogren’s Syndrome
- Ulcerative Colitis
- Systemic Lupus (SLE)
- Wegener’s Granulomatosis
How can one medicine influence such an extensive range of disorders?
All the disorders mentioned above share a common feature which is, in each of them the immune system performs a fundamental role. Hence low levels of endorphins in the blood are usually present, adding to the disease-associated immune deficiencies.
Researches on neuropeptide receptors revealed by several human tumors have discovered opioid receptors in various types of cancer:
- Brain tumors
- Lung cancer
- Head and neck squamous cell carcinoma
- Breast cancer
- Myeloid leukemia
- Endometrial cancer
- Neuroblastoma and others
So, these discoveries suggest the likelihood of an advantageous low-dose naltrexone outcome in a broad range of common cancers.
LDN has shown effectiveness in the treatment of numerous cases
During the mid of 2004, Dr. Bihari claimed of having treated more than 300 cancer patients who did not respond to regular treatments. From that group, around 50% of patients, following 4 to 6 months of treatment using low-dose naltrexone, started to exhibit a cessation in the growth of cancer and, among those, over 1 3rd have displayed objective indications of tumor shrinkage.
In the group of subjects who came forward with an autoimmune disease, none of them were unsuccessful in responding to low dose naltrexone, everyone experienced a pause in the progress of their disease. In several patients, a marked reduction in indications and symptoms of the disease was observed. The highest fraction of patients in the autoimmune disorder group is the individuals having multiple sclerosis. Fewer than 1% of those patients ever encountered a new attack of multiple sclerosis while maintaining their daily LDN nightly therapy.
Since 2003, Dr. Bihari had been using low-dose naltrexone in combination with trusted AIDS therapies to treat 350 AIDS patients. Over the previous 7 years, more than 85% of those patients revealed no HIV detectable levels, and it is considered a much greater success rate as compared to most prevailing AIDS treatments and includes no notable side effects. It is additionally worth remarking that several HIV/AIDS subjects have been surviving symptom-free over several years using only low-dose naltrexone with no additional medicines.
Central Nervous System disorders
Anecdotal statements remain being received concerning helpful consequences of LDN for the treatment of Parkinson’s disease, Amyotrophic lateral sclerosis (ALS—Lou Gehrig’s disease), Alzheimer’s disease, and primary lateral sclerosis. Dr. Jaquelyn McCandless claims to have found a highly positive impact of LDN, in the suitably reduced dose and applied topically as a transdermal cream in kids having autism.
LDN should be made by a well-reputed compounding pharmacy
Naltrexone is a prescription medicine, so your doctor would have to provide you a prescription after he/she decides that LDN seems suitable for you.
Low-dose naltrexone prescriptions are presently being filled by a number of local compounding pharmacies, and also by mail-order pharmacies, all over the US. Some pharmacists have been crushing up the 50mg naltrexone tablets to make the 4.5mg LDN capsules, while others make use of naltrexone, obtained from a primary manufacturer as a pure powder. Never attempt to divide naltrexone tablets by yourself to create low-dose naltrexone. Your consultant can assist you to locate a compounding pharmacy, such as Harbor Compounding Pharmacy, which prepares Low Dose Naltrexone.
LDN as treatment option_ a Miracle or a Myth
LDN still remains as another set of mysteries in the MS hype. Because you might have overheard people ranting about it, also you might have caught doctors hesitating from prescribing it. Who is right then?
Low Dose Naltrexone is more than ten times the reduced dosage of FDA-approved medicine – Naltrexone – 50 mg per day, which is given for opioid and alcohol dependence. Naltrexone works by obstructing toxic chemicals like heroin from exciting their response in the brain.
How does LDN treat diseases like MS?
In several regions of the human body, particularly the brain, the opioid receptors do not only relieve pain. Principally, these receptors connect with endogenous pain-relieving substances, like endorphins. Semi-synthetic elements, such as heroin, incite these receptors. Hence this function surfaces as a feedback loop, where obstructing these receptors slightly might create a rise in the production of endorphins.
Some people consider that these endorphins lessen the indications of autoimmune diseases like MS and also transform other chronic diseases. Endorphins appear to support healing too, and the restoration of cells as well as produce a positive impact on immune cells. Opioid receptors are located on these immune cells as well as some cancer cells. Exciting the opioid receptors might induce programmed cell death, known as apoptosis, of cancer cells.
One problem in knowing the consequences of LDN is that it both obstructs and excites the opioid receptors. This contradiction is comparable to what occurs in the immune system because of MS, so it can be challenging to understand because some elements that excite the immune system can cause it to become more vulnerable. This happens because the immune system is partially stimulated in MS, already. Due to these factors, comprehensive Low Dose Naltrexone research is required.
Some hope from Research
In the 1980s, physicians started prescribing Naltrexone at very lower doses, normally 3 to 4.5 mg, for autoimmune diseases, HIV, and cancer. Though, the scientific investigation did not start till 2006 when a clinical trial of Low Dose Naltrexone was carried in 17 people having Crohn’s disease. While LDN proved safe and efficient in this small research, it remained open-label, which means there was no comparison made with placebo or other randomization.
In 2008, experts in Italy announced the outcomes of an LDN’s Phase II trial conducted on 40 people encountering primary-progressive MS. Hence LDN was discovered to be ordinarily safe and decreased spasticity.
In 2010, scientists at the University of California along with Dr. Bruce Cree issued a placebo-controlled, crossover research on LDN including 80 patients of MS. In this controlled study, every person acted as their own “control” due to the crossover, implying that every participant got eight weeks of LDN treatment and eight weeks of placebo treatment. But, they were not told which treatment they were being given at any time.
LDN proved to be well-tolerated. So no serious side effects were reported and quality of life was enhanced.
Although these outcomes are all interesting unless one study undertaken in 2007 in Ohio gave negative results. This research of LDN concerning MS symptoms closed in 2008 stating no difference was observed between being treated with placebo or LDN. It is still unclear why that proved to be a negative study, So it would have been associated with problems concerning the design of the study, the patient group, or the number of subjects involved.
Side Effects of LDN
The most frequently reported side effects of LDN are sleep disruptions. This normally improves with time. However, it has not been confirmed, it is apparently better to administer Low Dose Naltrexone before sleep time because there is a slight blockage of opioid receptors within 2 a.m. to 4 a.m. So this is supposed to deliver a continued “up-regulation” of essential elements of the immune system through endorphin release.
It is commonly suggested that people using opiates for pain relief be detached from them following the advice of their doctor before starting LDN. This occurs because Naltrexone obstructs opioid receptors, and Low Dose Naltrexone might shift some of the influences. Additionally, LDN delivers extra endorphins release, which alone produces some pain relief.
Hence High doses of Naltrexone can result in liver problems and must not be given to people having liver diseases. It is not clear if such low doses of Naltrexone can induce liver issues, too, although the investigation has shown that LDN is usually safe.
People undergoing thyroid replacement medicine for an autoimmune disease named Hashimoto’s thyroiditis must begin taking LDN at lower doses. If the Low Dose Naltrexone serves to prevent the autoimmune system from attacking the thyroid, a chance remains that the thyroid hormone levels might rise too high. Thyroid hormone levels need to be checked regularly and LDN must particularly be taken under the attentive supervision of a trained physician.
If LDN remarkably produces a profound impact on the immune system, it is then possible that it can generate a damaging consequence on specific types of immune system disorders. Because this is why people using chemotherapies and immunosuppressive medicines should stay cautious regarding the usage of LDN.
Reference post article link: